Diabetes Metab J.  2020 Apr;44(2):260-266. 10.4093/dmj.2019.0007.

Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function

Affiliations
  • 1Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China
  • 2Department of Endocrinology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
  • 3Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China
  • 4Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China

Abstract

Background
The detection of glutamic acid decarboxylase 65 (GAD65) autoantibodies is essential for the prediction and diagnosis of latent autoimmune diabetes in adults (LADA). The aim of the current study was to compare a newly developed electrochemiluminescence (ECL)-GAD65 antibody assay with the established radiobinding assay, and to explore whether the new assay could be used to define LADA more precisely.
Methods
Serum samples were harvested from 141 patients with LADA, 95 with type 1 diabetes mellitus, and 99 with type 2 diabetes mellitus, and tested for GAD65 autoantibodies using both the radiobinding assay and ECL assay. A glutamic acid decarboxylase antibodies (GADA) competition assay was also performed to assess antibody affinity. Furthermore, the clinical features of these patients were compared.
Results
Eighty-eight out of 141 serum samples (62.4%) from LADA patients were GAD65 antibody-positive by ECL assay. Compared with ECL-GAD65 antibody-negative patients, ECL-GAD65 antibody-positive patients were leaner (P<0.0001), had poorer β-cell function (P<0.05), and were more likely to have other diabetes-associated autoantibodies. The β-cell function of ECLGAD65 antibody-positive patients was similar to that of type 1 diabetes mellitus patients, whereas ECL-GAD65 antibody-negative patients were more similar to type 2 diabetes mellitus patients.
Conclusion
Patients with ECL-GAD65 antibody-negative share a similar phenotype with type 2 diabetes mellitus patients, whereas patients with ECL-GAD65 antibody-positive resemble those with type 1 diabetes mellitus. Thus, the detection of GADA using ECL may help to identify the subtype of LADA.

Keyword

Autoantibodies; C-peptide; Glutamate decarboxylase; Latent autoimmune diabetes in adults

Figure

  • Fig. 1 Comparison of the radiobinding assay (RBA) and electrochemiluminescence (ECL) assay and differences in the affinity and number of autoantibodies, the area under the curve (AUC) for C-peptide in the various patient groups. (A) Glutamic acid decarboxylase antibodies (GADA) concentrations obtained using RBA and ECL assay were compared in latent autoimmune diabetes in adult (LADA) patients. (B) Affinity data for GADA-positive samples, classified according to ECL-GADA status. Serum samples with positive GADA by RBA from nine subjects (five ECL-GADA+ and four ECL-GADA−) were incubated with a range of concentrations of unlabeled glutamic acid decarboxylase 65 (GAD65) protein and analyzed using standard RBA. Positive samples detected by ECL-GADA assay (solid line) required less unlabeled GAD65 to reach a 50% maximal inhibition than those found to be negative (dotted line), which means positive samples are consistent with higher affinity. Results are expressed as percentages of the signal not absorbed. (C) The number of positive diabetes-associated autoantibodies in 88 ECL-GADA+ and 53 ECL-GADA− LADA samples. GADA was detected by ECL assay, IA2, and ZnT8 antibodies were detected by radioassay. (D) The AUC of C-peptide in LADA patients (ECL-GADA+ and ECL-GADA−), type 1 diabetes mellitus (T1DM) patients, and type 2 diabetes mellitus (T2DM) patients. aP<0.01 compared to T1DM, bP<0.05 compared to ECL-GADA+, cP<0.05 compared to ECL-GADA−.


Reference

1. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005; 48:2206–2212. PMID: 16193284.
Article
2. Palmer JP, Hirsch IB. What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care. 2003; 26:536–538. PMID: 12547896.
Article
3. Cernea S, Buzzetti R, Pozzilli P. Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care. 2009; 32:S246–S252. PMID: 19875559.
4. Jin P, Huang G, Lin J, Yang L, Xiang B, Zhou W, Zhou Z. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults. Clin Endocrinol (Oxf). 2011; 74:587–592. PMID: 21470281.
Article
5. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E. Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007; 30:932–938. PMID: 17392553.
Article
6. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD. Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013; 36:908–913. PMID: 23248199.
Article
7. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, Seissler J. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia. 2001; 44:1005–1010. PMID: 11484077.
Article
8. Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, Yang L, Lin J, Liu Z, Hagopian WA, Leslie RD. LADA China Study Group. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013; 62:543–550. PMID: 23086039.
Article
9. Krause S, Landherr U, Agardh CD, Hausmann S, Link K, Hansen JM, Lynch KF, Powell M, Furmaniak J, Rees-Smith B, Bonifacio E, Ziegler AG, Lernmark A, Achenbach P. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial. Diabetes Care. 2014; 37:1675–1680. PMID: 24598244.
Article
10. Achenbach P, Hawa MI, Krause S, Lampasona V, Jerram ST, Williams AJK, Bonifacio E, Ziegler AG, Leslie RD. Action LADA consortium. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia. 2018; 61:1644–1649. PMID: 29619531.
Article
11. Yu L. Islet autoantibody detection by electrochemiluminescence (ECL) assay. Methods Mol Biol. 2016; 1433:85–91. PMID: 26659802.
Article
12. Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L. Type 1 Diabetes TrialNet Study Group. Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther. 2015; 17:119–127. PMID: 25562486.
Article
13. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes. 1986; 35:237–241. PMID: 3510930.
Article
14. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K, Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab. 2010; 95:3360–3367. PMID: 20444913.
Article
15. Gu Y, Zhao Z, Miao D, High H, Yang T, Yu L. Electrochemiluminescence assays for human islet autoantibodies. J Vis Exp. 2018; 23:e57227.
Article
16. Liu L, Li X, Xiang Y, Huang G, Lin J, Yang L, Zhao Y, Yang Z, Hou C, Li Y, Liu J, Zhu D, Leslie RD, Wang X, Zhou Z. LADA China Study Group. Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). Diabetes Care. 2015; 38:16–21.
17. Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, Bonifacio E, Achenbach P. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes. 2007; 56:1527–1533. PMID: 17325256.
Article
18. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004; 114:589–597. PMID: 15314696.
Article
19. Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJ. Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol. 2012; 167:67–72. PMID: 22132886.
Article
20. Siljander H, Harkonen T, Hermann R, Simell S, Hekkala A, Salonsaari RT, Simell T, Simell O, Ilonen J, Veijola R, Knip M. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev. 2009; 25:615–622. PMID: 19637309.
Article
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr